Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the strategy of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps define momentum characteristics, with Medpace (MEDP) currently holding a Momentum Style Score of B [2][3] Group 2: Medpace Performance Metrics - Medpace has shown a 5.41% increase in shares over the past week, outperforming the Zacks Medical Services industry, which rose by 1.6% [5] - Over the past quarter, Medpace shares have risen by 55.26%, and by 18.27% in the last year, compared to the S&P 500's increases of 9.33% and 17.71% respectively [6] - The average 20-day trading volume for Medpace is 772,137 shares, indicating a bullish sign with rising stock prices [7] Group 3: Earnings Outlook - In the past two months, five earnings estimates for Medpace have increased, raising the consensus estimate from $12.71 to $13.99 [9] - For the next fiscal year, five estimates have also moved upwards, with no downward revisions during the same period [9] Group 4: Investment Recommendation - Considering the performance metrics and earnings outlook, Medpace is rated as a 2 (Buy) stock with a Momentum Score of B, making it a potential short-term investment opportunity [11]

Company Performance - Medpace reported quarterly earnings of $3.1 per share, exceeding the Zacks Consensus Estimate of $3 per share, and up from $2.75 per share a year ago, representing an earnings surprise of +3.33% [1] - The company posted revenues of $603.31 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 11.48%, compared to year-ago revenues of $528.1 million [2] - Over the last four quarters, Medpace has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Medpace shares have declined approximately 6.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $2.95 for the coming quarter and $12.68 for the current fiscal year [4][7] - The estimate revisions trend for Medpace was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Medpace belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The performance of Medpace's stock may also be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5][8]